Talha Badar

机构：Jacksonville College, WinnMed, Mayo Clinic in Arizona, Mayo Clinic in Florida · ORCID：0000-0003-1548-918X

发表论文 325 篇 · 总被引 2457 次 · h-index 25

代表论文

• Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy (2026 · American Journal of Hematology · 被引 5)
• Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias (2026 · Blood Advances · 被引 4)
• CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients (2026 · Blood Cancer Journal · 被引 2)
• Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database (2026 · Blood Cancer Journal · 被引 1)
• Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents (2026 · American Journal of Hematology · 被引 1)
• Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) (2026 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 1)